Therapeutic Treatment for Benign Prostatic Hyperplasia
Edited by Roger S. Kirby, John D. McConnell, John Fitzpatrick, Claus G. Roehrborn, Michael Wyllie, Peter Boyle
Published June 16th 2005 by CRC Press – 202 pages
The spectrum of available treatment options for benign prostatic hyperplasia (BPH) is matched by the spectrum of disease severity, and with up to 90% of men in their 80s suffering from BPH to some extent, it is imperative that patients are offered the full range of options to manage the disease.
Pharmacologic therapies available for the treatment of lower urinary tract symptoms secondary to BPH include alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin and tamsulosin, and the 5-alpha-reductase inhibitors, finasteride and dutasteride. Other strategies, such as plant-derived medication or watchful waiting, are applied to varying extents.
Derived from the benchmark title on BPH - Textbook of Benign Prostatic Hyperplasia - this well written and highly illustrated guide covers all these therapies and presents physicians with all they need to know to successfully manage the disease.
1. Medical Management - Watchful Waiting 2. The Placebo Effect in the Treatment of Benign Prostatic Hyperplasia 3. Dutasteride in the Treatment of the BPH Patient 4. Finasteride in the Treatment of Benign Prostatic Hyperplasia 5. Combination Therapy in the Treatment of BPH 6. The Differential Effects of Adrenoceptor Antagonists on Prostate Tissue Growth 7. Terazosin in the Treatment of the Lower Urinary Tract 8. Doxazosin in the Treatment of Benign Prostatic Hyperplasia 9. Alfuzosin 10. Tamsulosin 11. Phytotherapeutic Agents in the Treatment of LUTS and BPH 12. Uroselectivity Revisited